Immunotherapy最新文献_第3页

ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis.

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-02-01 Epub Date: 2025-02-26 DOI: 10.1080/1750743X.2025.2464528

Emma Guttman-Yassky, Eric Simpson, Robert Bissonnette, Lawrence F Eichenfield, Kenji Kabashima, Paula C Luna, Janá Tresnak Hercogová, Lynda Spelman, Margitta Worm, Ehsanollah Esfandiari, Takahiro Arai, Hirotaka Mano, Prista Charuworn, Andrea Wang, Gregory Kricorian

{"title":"ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis.","authors":"Emma Guttman-Yassky, Eric Simpson, Robert Bissonnette, Lawrence F Eichenfield, Kenji Kabashima, Paula C Luna, Janá Tresnak Hercogová, Lynda Spelman, Margitta Worm, Ehsanollah Esfandiari, Takahiro Arai, Hirotaka Mano, Prista Charuworn, Andrea Wang, Gregory Kricorian","doi":"10.1080/1750743X.2025.2464528","DOIUrl":"10.1080/1750743X.2025.2464528","url":null,"abstract":"Atopic dermatitis (AD) is a chronic inflammatory disease affecting ~ 10% of adults and ~ 20% of children globally. Many patients with moderate-to-severe AD receiving systemic therapies, including biologics and Janus kinase (JAK) inhibitors, fail to reach or maintain treatment goals due to lack of durable response or safety/tolerability issues. Rocatinlimab is a T-cell rebalancing therapy that inhibits and reduces pathogenic T cells by targeting the OX40 receptor. ROCKET, a large, global phase 3 program of eight clinical trials (NCT05398445; NCT05651711; NCT05724199; NCT05899816; NCT05704738; NCT05633355; NCT05882877; NCT06224192), will evaluate the efficacy, durability of response, and long-term safety of rocatinlimab as monotherapy and combination therapy in adult and adolescent patients with moderate-to-severe AD with or without prior exposure to biologics or systemic JAK inhibitors.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"83-94"},"PeriodicalIF":2.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11901500/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunotherapies for prevention and treatment of type 1 diabetes.

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-02-01 Epub Date: 2025-03-04 DOI: 10.1080/1750743X.2025.2473311

Rebecca Jeun

引用次数: 0

Extended survival of a patient with gastrointestinal multiple malignancies managed with anti-PD-1 immunotherapy: a case report.

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-02-01 Epub Date: 2025-02-11 DOI: 10.1080/1750743X.2025.2463309

Tianhao Guo, Yifan Hui, Wenjian Zhu, Fei Ke, Tingting Zhou, Wenli Qiu, Xuan Li, Liu Li, Haibo Cheng

{"title":"Extended survival of a patient with gastrointestinal multiple malignancies managed with anti-PD-1 immunotherapy: a case report.","authors":"Tianhao Guo, Yifan Hui, Wenjian Zhu, Fei Ke, Tingting Zhou, Wenli Qiu, Xuan Li, Liu Li, Haibo Cheng","doi":"10.1080/1750743X.2025.2463309","DOIUrl":"10.1080/1750743X.2025.2463309","url":null,"abstract":"Introduction: The annual rise in gastrointestinal cancer cases is evident, yet the occurrence of multiple primary malignancies remains comparatively uncommon. In recent years, immunotherapy has swiftly emerged as the leading treatment for several solid tumors, including gastrointestinal cancers. Single treatments might be ineffective, necessitating the need for comprehensive integrative medicine.Case description: This study reports a case of multiple cancers, including colorectal and gastric cancers. Diverse systemic treatments, like capecitabine, the combination of capecitabine and paclitaxel liposome, as well as capecitabine with toripalimab, were unsuccessful. Nevertheless, prolonged survival was attained through anti-PD-1 immunotherapy complemented by alternative medicine approaches. The patient has exceeded a 35-month survival post-initial diagnosis and 20-month survival since the subsequent diagnosis, markedly surpassing the prognosis often associated with advanced-stage multiple cancers.Conclusion: In summary, this case underscores the potential effectiveness of a holistic, integrative medical approach in managing advanced multiple malignancies amid drug resistance and disease progression.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"95-101"},"PeriodicalIF":2.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11901419/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143399130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pegcetacoplan for the treatment of geographic atrophy due to age-related macular degeneration: a plain language summary of OAKS and DERBY clinical studies. Pegcetacoplan用于治疗因年龄相关性黄斑变性引起的地理萎缩：OAKS和DERBY临床研究的简单语言总结。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-01-17 DOI: 10.1080/1750743X.2025.2449760

Jeffrey S Heier, Eleonora M Lad, Frank G Holz, Philip J Rosenfeld, Robyn H Guymer, David Boyer, Federico Grossi, Caroline R Baumal, Jean-Francois Korobelnik, Jason S Slakter, Nadia K Waheed, Ravi Metlapally, Ian Pearce, Nathan Steinle, Anibal A Francone, Allen Hu, David R Lally, Pascal Deschatelets, Cedric Francois, Caleb Bliss, Giovanni Staurenghi, Jordi Monés, Rishi P Singh, Ramiro Ribeiro, Charles C Wykoff

引用次数: 0

Survival impact of immune-related adverse events in extensive stage small cell lung cancer patients: a retrospective cohort study.

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-01-01 Epub Date: 2025-01-23 DOI: 10.1080/1750743X.2025.2456448

John C Hunting, Sarah N Price, Andrew T Faucheux, Eric Olson, Catherine A Elko, Alexander Quattlebaum, Jimmy Ruiz, Thomas William Lycan

{"title":"Survival impact of immune-related adverse events in extensive stage small cell lung cancer patients: a retrospective cohort study.","authors":"John C Hunting, Sarah N Price, Andrew T Faucheux, Eric Olson, Catherine A Elko, Alexander Quattlebaum, Jimmy Ruiz, Thomas William Lycan","doi":"10.1080/1750743X.2025.2456448","DOIUrl":"10.1080/1750743X.2025.2456448","url":null,"abstract":"Background: Prior research indicates a connection between immune-related adverse events (irAEs) and improved progression-free survival (PFS) and overall survival (OS) in non-small cell lung cancer. However, limited data exists for extensive stage small cell lung cancer (ES-SCLC).Methods: This study included all ES-SCLC patients who received at least one dose of an immune checkpoint inhibitor between 2 January 2011 and 4 July 2022 using a large retrospective registry from a single institution. PFS and OS were right-censored at the date of last follow-up and were estimated using the Kaplan-Meier method. Differences in PFS and OS between irAE groups were assessed using Cox proportional hazards models.Results: Among 245 patients with ES-SCLC; 56 (23%) experienced irAEs, 24 (42.9%) of which were high-grade (3-4). High-grade irAEs occurred at a median of 1.2 months (interquartile range [IQR] 0.45-2.5), while low-grade irAE occurred at 2.8 months (1.3-5.2). PFS was significantly longer among any irAE vs none (HR = 0.49; [95%CI 0.32-0.77]) as was OS (HR = 0.49; [95%CI 0.34-0.72]).Conclusions: In ES-SCLC patients treated with immunotherapy, those who experienced any irAE demonstrated a two-fold increase in both PFS and OS compared to those without an irAE. This is consistent with other tumor primaries.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"19-24"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834449/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143023286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Disparities in utilization of novel cancer therapies in advanced stage III and IV melanoma and variance in outcomes. 在晚期III期和IV期黑色素瘤中使用新型癌症疗法的差异和结果的差异。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-01-01 Epub Date: 2025-01-18 DOI: 10.1080/1750743X.2025.2452836

Mohammad S Ali, Jae Ahn, N Joseph Espat, Abdul S Calvino, James Koness, Ponnandai Somasundar, Steve Kwon

{"title":"Disparities in utilization of novel cancer therapies in advanced stage III and IV melanoma and variance in outcomes.","authors":"Mohammad S Ali, Jae Ahn, N Joseph Espat, Abdul S Calvino, James Koness, Ponnandai Somasundar, Steve Kwon","doi":"10.1080/1750743X.2025.2452836","DOIUrl":"10.1080/1750743X.2025.2452836","url":null,"abstract":"Introduction: Significant gains in advanced melanoma have been made through immunotherapy trials. Factors influencing equitable access and survival impact of these novel therapies are not well-defined.Method: Retrospective analysis using National Cancer Database of patients with advanced stage III and IV melanoma from 2004 to 2021. Multivariable logistic regression was used to study the use of immunotherapy and Cox proportional hazard regression to evaluate overall survival (OS).Results: 47,427 patients with increasing utilization of immunotherapy from 13.78% in 2004 to 65.88% by 2021. Inequitable adoption were impacted by age, sex, socioeconomic status/affordability, insurance types and residential educational/income level. Receiving immunotherapy was associated with a 44% improvement in OS (HR 0.56, 95% CI 0.54-0.57) and receiving a clinical trial-based therapy was associated with a 37% improvement (HR 0.63, 95% CI 0.53-0.75). Among patients who received immunotherapy or clinical trial-base therapy, there was 40% worse survival in non-Hispanic Black patients (HR 1.40, 95% CI 1.16-1.69) compared to non-Hispanic Whites.Conclusion: There are disparities in utilization of immunotherapy that is influenced by socioeconomic status. Race and ethnicity had a significant influence in differential impact on survival outcomes of immunotherapies highlighting the importance of increasing underrepresented population participation in trials that lead to novel therapies.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"37-46"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143004823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the role of immunotherapy in the management of follicular cell-derived thyroid cancer.

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-01-01 Epub Date: 2025-02-03 DOI: 10.1080/1750743X.2025.2455922

Paige Benson, Omar Abdel-Rahman

引用次数: 0

Immunotherapy-related secondary hemophagocytosis in a glioblastoma patient: response to cytokine-directed therapy. 胶质母细胞瘤患者免疫治疗相关的继发性噬血细胞症：对细胞因子导向治疗的反应。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-01-01 Epub Date: 2025-01-15 DOI: 10.1080/1750743X.2025.2451604

Ozkan Alan, Mustafa Cem Bulbul, Mehmet Ali Enlice, Nil Molinas Mandel

引用次数: 0

Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations. Hb与RDW比值在一线免疫治疗联合治疗转移性肾癌患者中的作用。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-01-01 Epub Date: 2025-01-20 DOI: 10.1080/1750743X.2025.2452145

Matilde Corianò, Alessandro Lazzarin, Michele Maffezzoli, Matteo Santoni, Giulia Mazzaschi, Sara Rodella, Nicola Simoni, Eleonora Lai, Marco Maruzzo, Umberto Basso, Davide Bimbatti, Roberto Iacovelli, Annunziato Anghelone, Ondřej Fiala, Sara Elena Rebuzzi, Giuseppe Fornarini, Cristian Lolli, Francesco Massari, Matteo Rosellini, Veronica Mollica, Cecilia Nasso, Alessandro Acunzo, Enrico Maria Silini, Federico Quaini, Massimo De Filippo, Matteo Brunelli, Giuseppe L Banna, Pasquale Rescigno, Alessio Signori, Sebastiano Buti

{"title":"Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations.","authors":"Matilde Corianò, Alessandro Lazzarin, Michele Maffezzoli, Matteo Santoni, Giulia Mazzaschi, Sara Rodella, Nicola Simoni, Eleonora Lai, Marco Maruzzo, Umberto Basso, Davide Bimbatti, Roberto Iacovelli, Annunziato Anghelone, Ondřej Fiala, Sara Elena Rebuzzi, Giuseppe Fornarini, Cristian Lolli, Francesco Massari, Matteo Rosellini, Veronica Mollica, Cecilia Nasso, Alessandro Acunzo, Enrico Maria Silini, Federico Quaini, Massimo De Filippo, Matteo Brunelli, Giuseppe L Banna, Pasquale Rescigno, Alessio Signori, Sebastiano Buti","doi":"10.1080/1750743X.2025.2452145","DOIUrl":"10.1080/1750743X.2025.2452145","url":null,"abstract":"Background: The present study aimed to investigate the prognostic and predictive roles of Hb/RDW ratio in patients with mRCC treated with first-line immunotherapy combinations (TKI plus ICI or ICI plus ICI).Materials and methods: We performed a sub-analysis of a multicenter retrospective observational study (ARON-1 project) involving patients with mRCC treated with first-line immunotherapy combinations.Results: Three hundred and twenty-nine patients were enrolled, 244 males and 85 females. Median age was 65.5 years. The prognostic impact of the Hb/RDW ratio on PFS and OS was observed in the whole population examined. Hb/RDW ratio had a correlation with neutrophil-to-lymphocyte ratio (NLR), a blood inflammatory parameter.Conclusion: Hb/RDW ratio is a new inflammatory prognostic factor, easy to use in daily clinical practice.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"25-35"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143004827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anakinra in relapsing polychondritis: a case report and review of the literature. 阿那金治疗复发性多软骨炎1例报告及文献复习。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-01-01 Epub Date: 2024-12-20 DOI: 10.1080/1750743X.2024.2443381

Syed B Ali, Tiffany Hughes, Anthony Smith

{"title":"Anakinra in relapsing polychondritis: a case report and review of the literature.","authors":"Syed B Ali, Tiffany Hughes, Anthony Smith","doi":"10.1080/1750743X.2024.2443381","DOIUrl":"10.1080/1750743X.2024.2443381","url":null,"abstract":"Relapsing polychondritis is rare and affects non-synovial fibrocartilage. Currently, there is a paucity of treatment algorithms, especially for those with refractory disease. A middle-aged man presented with polychondritis affecting the nose, ears, joints, and larynx. Two months prior, a diagnosis of non-arteritic ischemic optic neuropathy was made. Oral prednisolone was initiated, and over the following three years, he had several flares for which the following other treatments were given: moderate dose methotrexate (elevated liver enzymes), azathioprine (gastrointestinal intolerance), mycophenolate (ineffective), tocilizumab (widespread eruption), and tofacitinib (acute diverticulitis). Further investigations were unremarkable for malignancy and vasculitis. UBA1 mutation screening was negative. Given the limited therapeutic options, methotrexate at a lower dose was re-added, but he developed acute flare with laryngeal symptoms. Anakinra was initiated, prompting a successful prednisolone wean over the following weeks and disease remission. A literature review identified 11 publications comprising 25 patients. Of the 21 patients with anakinra response documented, six (28.6%) had symptomatic improvement. In one of these patients, there was co-administration of methotrexate. In summary, anakinra may remain as an option, only for those subsets of patients in whom many of the other more efficacious treatments have been tried to provide sustained disease control.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"5-9"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834529/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142864162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0